Fasting Triglycerides: Longevity-Medicine Target Ranges

What Are Fasting Triglycerides and Why Does Fasting Matter?

Triglycerides are the dominant storage form of dietary fat, circulating in the blood packaged inside very-low-density lipoprotein (VLDL) particles. A fasting measurement, taken after 9 to 12 hours without caloric intake, removes the variable contribution of chylomicrons from a recent meal and gives a stable, reproducible baseline that reflects hepatic VLDL secretion and lipoprotein lipase activity.

Why the Fasting State Changes the Number

A non-fasting draw can add 20 to 50 mg/dL transiently, which may push a borderline patient into an apparently high range. The 2018 ACC/AHA Cholesterol Guideline explicitly recommends fasting sampling when triglycerides are being used to calculate LDL-C via the Friedewald equation, because the equation's accuracy degrades above 400 mg/dL and is distorted by non-fasting chylomicrons. [1]

Physiological Sources of Triglycerides

Hepatic de novo lipogenesis, driven primarily by excess dietary carbohydrate and fructose, accounts for the majority of elevated fasting triglycerides in the modern metabolic phenotype, not dietary fat intake directly. Alcohol is a second major driver: even moderate consumption (two standard drinks per day) can raise fasting triglycerides by 50 mg/dL or more in susceptible individuals. [2]

Uncontrolled type 2 diabetes and hypothyroidism both impair lipoprotein lipase activity, which clears VLDL from circulation. Any triglyceride result above 200 mg/dL without an obvious dietary explanation warrants a thyroid-stimulating hormone (TSH) test and hemoglobin A1c.

Standard Reference Ranges and Guideline Cut-Points

The ATP III classification from the National Cholesterol Education Program, adopted into the 2018 ACC/AHA guideline, divides fasting triglyceride levels into five categories. These thresholds remain the most widely cited in clinical practice.

| Category | Fasting Triglyceride Level | |---|---| | Normal | <150 mg/dL (<1.69 mmol/L) | | Borderline high | 150 to 199 mg/dL | | High | 200 to 499 mg/dL | | Very high | ≥500 mg/dL |

ATP III and the Metabolic Syndrome Threshold

ATP III designates ≥150 mg/dL as one of the five criteria for metabolic syndrome. Meeting three of the five criteria (elevated waist circumference, elevated fasting glucose, elevated blood pressure, low HDL-C, and elevated triglycerides) confers an approximately threefold increased risk of type 2 diabetes and a twofold increased risk of cardiovascular disease compared with individuals meeting zero criteria. [3]

The AHA/NHLBI Harmonized Definition

The harmonized 2009 Joint Statement from the AHA, NHLBI, IDF, and other bodies kept the ≥150 mg/dL triglyceride cut-point unchanged. It also noted that a triglyceride-to-HDL ratio above 3.0 (mg/dL units) is a practical surrogate marker for small, dense LDL-B phenotype and insulin resistance, both of which carry cardiovascular risk independent of LDL-C. [4]

The Longevity-Medicine Target: Why <100 mg/dL?

The standard laboratory "normal" of <150 mg/dL was designed as a population-based disease threshold, not an optimized longevity target. Longevity-medicine clinicians, drawing on observational cohort data and VLDL particle physiology, have converged on <100 mg/dL as the performance target.

Epidemiological Evidence Supporting the <100 mg/dL Goal

The Copenhagen City Heart Study (N=13,981, follow-up 26 years) demonstrated a graded, independent relationship between non-fasting triglycerides and cardiovascular mortality. Individuals in the top versus bottom tertile of triglycerides had a hazard ratio for myocardial infarction of 2.0 in men and 2.8 in women after multivariable adjustment. [5] Critically, excess risk began accumulating well below the 150 mg/dL clinical threshold, with the lowest risk concentrated in participants whose triglycerides remained below 89 mg/dL.

In the Women's Health Study (N=26,509), Ridker et al. Reported that non-fasting triglycerides were among the strongest single lipid predictors of incident cardiovascular events in women, outperforming LDL-C in adjusted models. Triglyceride levels in the highest quintile (≥201 mg/dL) versus lowest (<74 mg/dL) were associated with a 5.0-fold increased risk of future cardiovascular events. [6]

VLDL Particle Biology and Atherogenicity

Elevated fasting triglycerides are a proxy for elevated VLDL particle number. VLDL remnants, also called intermediate-density lipoprotein (IDL) particles, are directly atherogenic. They penetrate the arterial intima and deposit cholesterol in plaque in the same way small dense LDL does. The Mendelian randomization literature has now established that triglyceride-rich lipoprotein remnant cholesterol is causally associated with atherosclerosis, independent of LDL-C. [7]

A fasting triglyceride level of 90 mg/dL corresponds to a very-low VLDL particle burden, minimal remnant cholesterol, and favorable hepatic insulin sensitivity. A level of 145 mg/dL, though still technically "normal," may reflect a metabolic state of early hepatic fat accumulation and insulin resistance that precedes overt disease by years to decades.

The HealthRX Longevity Triglyceride Framework

Clinicians on the HealthRX medical team apply a three-tier interpretation scheme to fasting triglyceride results:

1. Performance zone (<100 mg/dL). Consistent with low remnant cholesterol burden, favorable insulin sensitivity, and absence of hepatic fat accumulation by most imaging criteria. No intervention required beyond maintaining current lifestyle.
2. Watchful zone (100 to 149 mg/dL). Lab-normal but metabolically suboptimal. Warrants dietary carbohydrate and fructose audit, waist circumference measurement, fasting insulin or HOMA-IR calculation, and reassessment in 90 days after lifestyle modification.
3. Intervention zone (≥150 mg/dL). Meets the metabolic syndrome triglyceride criterion. Requires a structured treatment plan that may include dietary modification, omega-3 fatty acid supplementation, and, at higher levels, prescription pharmacotherapy.

Fasting Triglycerides and Metabolic-Associated Steatotic Liver Disease (MASLD)

The condition formerly called non-alcoholic fatty liver disease (NAFLD) was renamed metabolic-associated steatotic liver disease (MASLD) in a 2023 Delphi consensus. Fasting triglycerides are embedded in its diagnostic criteria.

MASLD Diagnostic Criteria Include Triglycerides

The Delphi consensus defined MASLD as hepatic steatosis on imaging (or liver biopsy) plus at least one of five cardiometabolic risk factors. One of those five risk factors is fasting triglycerides ≥150 mg/dL (or on triglyceride-lowering pharmacotherapy). [8] This makes fasting triglycerides a formal diagnostic criterion, not merely an associated finding.

Triglycerides as a Marker of Hepatic Fat

Hepatic de novo lipogenesis simultaneously elevates fasting triglycerides and deposits intrahepatic fat. Controlled overfeeding studies show that isocaloric fructose overfeeding raises fasting triglycerides by an average of 40% within two weeks, with parallel increases in intrahepatic lipid measured by magnetic resonance spectroscopy. [9] This mechanistic link means that fasting triglyceride trends serve as an inexpensive surrogate for hepatic fat changes between imaging studies.

Fibrosis Progression Risk

The NASH Clinical Research Network showed that patients with biopsy-confirmed NAFLD who also had baseline triglycerides above 150 mg/dL had significantly faster progression to bridging fibrosis over a 4-year observation period compared to those with triglycerides below 100 mg/dL. [10] This finding reinforces the case for treating triglycerides to the <100 mg/dL longevity target rather than accepting lab-normal values.

Cardiovascular Risk: Triglycerides Beyond LDL-C

LDL-C reduction via statins remains the cornerstone of cardiovascular prevention. Yet residual cardiovascular risk persists even in patients on high-intensity statin therapy with LDL-C well below 70 mg/dL. Elevated triglycerides, specifically elevated remnant cholesterol, contribute to this residual risk.

REDUCE-IT Trial Evidence

The REDUCE-IT trial (N=8,179) enrolled statin-treated patients with established cardiovascular disease or diabetes plus at least one additional risk factor, all of whom had fasting triglycerides between 135 and 499 mg/dL. Treatment with icosapentaenoic acid (IPE, icosapent ethyl / Vascepa) 4 g/day reduced the primary composite cardiovascular endpoint by 25% relative to placebo (hazard ratio 0.75, 95% CI 0.68 to 0.83, P<0.001) over a median 4.9 years. [11] This trial established that triglyceride-lowering in the 135 to 499 mg/dL range provides cardiovascular benefit independent of LDL-C reduction.

STRENGTH Trial: Where Omega-3 Mixtures Failed

The STRENGTH trial (N=13,078) tested a combination of EPA plus DHA (omega-3 carboxylic acids, 4 g/day) and found no significant reduction in major adverse cardiovascular events (hazard ratio 0.99, 95% CI 0.90 to 1.09). [12] The divergence between REDUCE-IT and STRENGTH remains under debate. The leading hypothesis is that pure EPA (icosapent ethyl) has anti-inflammatory and membrane-stabilizing properties beyond triglyceride lowering that DHA-containing formulas do not share. For clinical practice, only icosapent ethyl (IPE) has FDA approval for cardiovascular risk reduction in patients with elevated triglycerides on statin therapy.

The Remnant Cholesterol Concept

The 2022 European Society of Cardiology (ESC) dyslipidemia guideline introduced remnant cholesterol as a separate therapeutic target, calculated as total cholesterol minus LDL-C minus HDL-C. An ESC guideline statement reads: "Remnant cholesterol is a causal risk factor for ischemic heart disease and all-cause mortality, and plasma levels should be considered in cardiovascular risk assessment." [13] Fasting triglycerides directly predict remnant cholesterol, making them a practical proxy when full lipoprotein particle testing (NMR or ion mobility) is not available.

Who Gets Elevated Fasting Triglycerides? Risk Factor Profile

Dietary Drivers

Refined carbohydrates and fructose-sweetened beverages are the most modifiable dietary drivers. Sugar-sweetened beverage consumption of one or more servings per day raises fasting triglycerides by an average of 15 to 20 mg/dL in controlled feeding studies. [14] Alcohol, even in modest quantities, contributes substantially in individuals with genetic susceptibility (APOC3 or LPL variants).

Genetic Causes

Familial hypertriglyceridemia (FHTG) and familial combined hyperlipidemia (FCH) together affect approximately 1 in 200 adults and can push fasting triglycerides above 400 mg/dL despite an otherwise healthy lifestyle. Severe hypertriglyceridemia above 500 mg/dL should prompt genetic testing for lipoprotein lipase deficiency (LPL loss-of-function variants) or APOC2 mutations. Acute pancreatitis risk rises sharply above 1,000 mg/dL and becomes an independent indication for pharmacotherapy. [15]

Hormonal and Pharmacological Contributors

Estrogen (oral, not transdermal) raises VLDL secretion and can increase fasting triglycerides by 20 to 50 mg/dL. Transdermal estradiol has a neutral to mildly favorable effect on triglycerides. Tamoxifen can increase triglycerides substantially, occasionally to pancreatitis-level values. Beta-blockers, thiazide diuretics, second-generation antipsychotics (particularly olanzapine and clozapine), and glucocorticoids all raise fasting triglycerides through distinct mechanisms.

How to Lower Fasting Triglycerides: Evidence-Based Interventions

Dietary Modification (First-Line)

Replacing refined carbohydrates with whole foods, eliminating sugar-sweetened beverages, and reducing alcohol intake typically lowers fasting triglycerides by 20 to 50 mg/dL within 4 to 8 weeks. A meta-analysis of 23 randomized controlled trials found that low-carbohydrate diets (defined as <130 g/day carbohydrate) reduced fasting triglycerides by a mean of 28 mg/dL compared with low-fat diets (P<0.001). [16]

Aerobic Exercise

Aerobic exercise at moderate intensity (150 minutes per week of brisk walking or equivalent) reduces fasting triglycerides by approximately 10 to 15% through enhanced lipoprotein lipase activity in skeletal muscle. A 2007 meta-analysis in Archives of Internal Medicine (N=4,700 across 25 trials) reported a net mean reduction of 3.7 mg/dL per MET-hour of additional weekly activity, with greater reductions in those starting above 150 mg/dL. [17]

Weight Loss

Each 5% reduction in body weight reduces fasting triglycerides by approximately 15 to 20 mg/dL. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg subcutaneous weekly produced a mean body weight reduction of 14.9% at 68 weeks versus 2.4% with placebo, accompanied by clinically meaningful improvements in fasting triglycerides, HDL-C, and blood pressure. [18]

Pharmacotherapy

Fibrates. Fenofibrate and gemfibrozil activate PPAR-alpha, reducing VLDL secretion and increasing lipoprotein lipase activity. Fenofibrate lowers fasting triglycerides by 30 to 50% and is the preferred fibrate in statin-combination therapy due to lower myopathy risk than gemfibrozil.

High-dose omega-3 fatty acids. Prescription omega-3 formulations at 4 g/day lower fasting triglycerides by 20 to 30% in patients with baseline levels above 500 mg/dL and by roughly 15 to 20% at baseline levels of 200 to 499 mg/dL. As noted, only icosapent ethyl (Vascepa) carries FDA approval for cardiovascular risk reduction.

Niacin. Extended-release niacin at 1 to 2 g/day lowers triglycerides by 20 to 40%, but two large outcome trials (AIM-HIGH and HPS2-THRIVE) showed no incremental cardiovascular benefit when added to statin therapy, and the drug carries significant flushing and hepatotoxicity risk. Use is now limited to refractory cases.

Interpreting Trends Over Time, Not Single Values

A single fasting triglyceride measurement carries measurement variability of approximately 15 to 20% within-person day-to-day. The ACC/AHA guideline recommends basing treatment decisions on the average of two fasting measurements taken at least one week apart, particularly in the borderline-high range. [1] Trending the triglyceride-to-HDL ratio across visits (target <2.0 in mg/dL units) adds diagnostic precision for tracking insulin sensitivity over time without requiring expensive particle testing.

Special Populations

Women on Menopausal Hormone Therapy

Oral estrogen raises fasting triglycerides. Women with pre-treatment triglycerides above 150 mg/dL should use transdermal estradiol, which bypasses first-pass hepatic metabolism and does not increase VLDL secretion. The KEEPS trial (N=727) confirmed that transdermal estradiol had a neutral effect on fasting triglycerides over 48 months, while oral conjugated equine estrogen raised them by 12 mg/dL on average. [19]

Patients with Type 2 Diabetes

Insulin resistance directly impairs lipoprotein lipase and promotes hepatic VLDL overproduction. In patients with diabetes, treating fasting triglycerides above 200 mg/dL with fenofibrate reduces diabetic retinopathy progression, as shown in the FIELD trial (N=9,795), where fenofibrate reduced laser treatment for retinopathy by 30% (P<0.001) regardless of baseline triglyceride level. [20]